Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 382

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

ANTI-HLA ANTIBODIES AFTER SOLID ORGAN TRANSPLANTATION1

McKenna, Rachel M., Takemoto, Steven K., Terasaki, Paul I.·2000·Transplantation

Abstract

Abbreviations: BOS, bronchiolitis obliterans, CDC, complement-dependent cytotoxicity, PRA, panel-reactive antibody. One of the earliest controversies in the field of transplantation, after the demonstration by Brent that the homograft (allograft) reaction was immunologic, was whether grafts are rejected by humoral or cellular mechanisms (1).Currently the cellular theory of graft rejection dominates. However, despite many attempts to detect the pretransplantation state of immunization by testing T lymphocyte function, only the humoral anti-HLA panel-reactive antibody (PRA*) test (2) has been effective in measuring alloimmunization. The clinical relevance of the humoral response was clearly demonstrated in 1969 in a study that showed that HLA antibodies can instantly kill an entire kidney (3). Two excellent reviews were published recently, showing that patients with pretransplantation anti-HLA PRA have an increased risk of graft failure (4, 5). Thus it is now routine to measure anti-HLA antibodies before transplantation. However posttransplantation monitoring of anti-HLA antibodies is not performed routinely. Recent advances in the techniques used to detect anti-HLA antibodies, as well as a substantial number of studies showing an association of posttransplantation anti-HLA antibodies with adverse events, suggest that such testing may be clinically useful as well as give some insight into the mechanism of graft rejection. In this review, we will describe advances in HLA antibody testing and recent studies to determine the relevance of posttransplantation HLA antibody in solid organ transplantation. We summarize the evidence that HLA antibodies developed after transplantation are associated with acute as well as chronic rejection of allografts. On a historical note, the first posttransplantation antibody study was performed in 1968 on 24 patients who underwent transplantation in Richmond, Virginia (6). The presence of HLA antibodies detected by complement-dependent cytotoxicity (CDC) was associated with poor function of the kidney transplants. Early studies on the detection of HLA antibodies were based on the standard lymphocyte cytotoxicity test (7). Renewed interest in posttransplantation antibodies has been driven by enhancements in the CDC assay (8) and the recent development of more sensitive and specific ELISA (9, 10) and flow cytometry tests (11–14). Using these tests, the association of HLA antibodies with rejection is becoming clearer and stronger. Methods to Detect Anti-HLA Antibodies CDC. This is the original assay in use for more than 30 years to detect antibodies to HLA antigens (7). Prepared plates containing live lymphocytes from 60 to 96 different individuals can be tested at once against any unknown serum to determine its specificity and extent of reactivity (PRA level). Additionally, reactivity against only donor target cells (T or B lymphocytes) can also be tested for. The greatest drawback of the CDC test is that it also detects non-HLA autoantibodies. Attempts to circumvent this complication consisted of incubating the test at 37°C to avoid reactions of cold autoantibodies and the addition of dithiothreitol to the serum to inactivate IgM antibodies. Because some strong autoantibodies, present particularly in patients with systemic lupus erythematosus, are IgG (15), dithiothreitol does not completely solve the problem of excluding extraneous reactions. A possible reason that early attempts to monitor the development of donor-specific antibody failed may be due to the fact that the CDC assay requires complement fixation and lysis of target lymphocytes to measure antibody reactivity. Fuller et al. (8) described a phenomenon whereby antibody that did not react by CDC to donor antigens could be removed by absorption with donor platelets. The addition of an antihuman immunoglobulin reagent revealed donor reactivity and markedly increased the sensitivity of HLA antibody characterization by increasing the efficiency of complement C1q binding (16). This modification of the CDC assay is now used routinely in many HLA laboratories to detect anti-HLA antibodies. Flow cytometry. This assay uses a laser beam to detect antibodies using a similar second antihuman immunoglobulin antibody that is linked to a fluorescent marker. With this assay, antibodies can be detected with 10- to 250-fold greater sensitivity than the CDC test. T and B lymphocytes are generally used as targets to distinguish anti-HLA class I from class II reactivity. Complement fixation is unnecessary, and the isotype of the antibody can be determined by using fluorescent labeled anti-human globulin isotype-specific reagents (e.g., anti-human IgG or anti-human IgM). Finally, the intensity of the reaction, which is related to the ratio of antibody molecules per target antigen, can be determined quantitatively by median channel shift (17) or relative change in fluorescence ratio (18). One difficulty, if living cells are used as targets, is

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00007890-200002150-00001

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 382

Metadata

Authors
McKenna, R. M., Takemoto, S. K., & Terasaki, P. I.
Venue
Transplantation
Published
2000-02
Volume
69
Issue
3
Pages
319-326
ISSN
0041-1337 (ISSN-L)
OpenAlex
W2072492485
Cited by
382
References
14
FWCI
16.18
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ANTI-HLA ANTIBODIES AFTER SOLID ORGAN TRANSPLANTATION1. https://app.cochat.ai/papers/10.1097/00007890-200002150-00001
The paper
McKenna, R. M., Takemoto, S. K., & Terasaki, P. I. (2000). ANTI-HLA ANTIBODIES AFTER SOLID ORGAN TRANSPLANTATION1. Transplantation. https://doi.org/10.1097/00007890-200002150-00001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.